We are live on ! Find out more
IGC icon

IGC Pharma
IGC

4 hedge funds and large institutions have $108K invested in IGC Pharma in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.73% less ownership

Funds ownership: 1.51% → 0.78% (-0.73%)

71% less capital inflows, than outflows

Capital inflows: $482K | Capital outflows: $1.65M

80% less funds holding

Funds holding: 20 → 4 (-16)

89% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 18

Holders
4
Holders Change
-16
Holders Change %
-80%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Dearborn Partners
Dearborn Partners
Illinois
+$476K
2
Carroll Financial Associates
Carroll Financial Associates
North Carolina
+$5.11K
3
Simplex Trading
Simplex Trading
Illinois
+$1.02K

Top Sellers

Rank Fund Capital Flow
1
Creative Planning
Creative Planning
Kansas
-$420K
2
HSBC Holdings
HSBC Holdings
United Kingdom
-$385K
3
Suntrust Banks
Suntrust Banks
Georgia
-$355K
4
Jane Street
Jane Street
New York
-$137K
5
ING Group
ING Group
Netherlands
-$97K

IGC Hedge Fund Activity: Q4 2018 in Review

4 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q4 2018, worth a combined $108K — down 96% from $3.07M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of IGC and 2 opened new positions — a net loss of 16 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Dearborn Partners, opening a new position worth an estimated $476K. The largest seller was Creative Planning, exiting entirely with an estimated $420K sold.

  • 4 institutional investors held IGC Pharma (IGC) as of Q4 2018, down from 20 in Q3 2018.
  • Funds reported $108K of IGC Pharma stock for Q4 2018, down 96% quarter-over-quarter.
  • 2 funds opened new IGC Pharma positions in Q4 2018 and 18 closed out, a net change of -16 holders.
  • The largest IGC Pharma buyer in Q4 2018 was Dearborn Partners, an estimated $476K added.
  • The largest IGC Pharma seller in Q4 2018 was Creative Planning, an estimated $420K sold.

Based on aggregated 13F filings for Q4 2018.